Abstract
It has been known for 50 years that transaminase activity increases in patients with acute myocardial infarction. With the development of creatine kinase (CK), biomarkers of cardiac injury began to take a major role in the diagnosis and management of patients with acute cardiovascular disease. In 2000 the European Society of Cardiology and the American College of Cardiology recognized the pivotal role of biomarkers and made elevations in their levels the "cornerstone" of diagnosis of acute myocardial infarction. At that time, they also acknowledged that cardiac troponin I and T had supplanted CK-MB as the analytes of choice for diagnosis. In this review, we discuss the science underlying the use of troponin biomarkers, how to interpret troponin values properly and how to apply these measurements to patients who present with possible cardiovascular disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1191-1202 |
| Number of pages | 12 |
| Journal | Canadian Medical Association Journal |
| Volume | 173 |
| Issue number | 10 |
| DOIs | |
| State | Published - Nov 8 2005 |
ASJC Scopus subject areas
- General Medicine